National Research ( (NRC) ) has released its Q2 earnings. Here is a breakdown of the information National Research presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
National Research Corporation, operating as NRC Health, is a company dedicated to humanizing healthcare through its unique approach to understanding patient experiences and preferences. It operates primarily in the healthcare sector, providing market research and consumer insights to healthcare systems.
In its second-quarter 2025 earnings report, NRC Health announced a continuation of positive trends with a third consecutive quarter of sequential growth in Total Recurring Contract Value (TRCV). The company has also reinstated its quarterly earnings call, reflecting its commitment to transparency and investor engagement.
Key financial highlights include a 2% sequential growth in TRCV, marking the highest growth rate since early 2021. The company’s adjusted EBITDA margin stood at 30%, demonstrating stability despite a net margin of 0% due to non-recurring executive compensation expenses. Additionally, NRC Health declared a quarterly cash dividend and continued its stock repurchase program, returning a total of $16.1 million to shareholders in 2025.
Despite a reported net loss for the quarter, NRC Health’s strategic focus on customer retention and product portfolio enhancement has shown positive results. The company’s financial performance is supported by a stronger sales team and a robust customer service organization, which have contributed to improved sales and retention metrics.
Looking ahead, NRC Health’s management remains optimistic about the company’s trajectory, emphasizing ongoing efforts to align with long-term shareholder interests and enhance its market position through strategic initiatives and cost control measures.